SynthesisScientific reports2020
A systematic review and meta-analysis of effects of menopausal hormone therapy on cardiovascular diseases.
Synthesis in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 3 syntheses or guidelines pooled it, 97 citations in OpenAlex.
- [Preventive activities in women: PAPPS 2024 update].Atencion primaria · 2024Guideline
- Brazilian Guideline on Menopausal Cardiovascular Health - 2024.Arquivos brasileiros de cardiologia · 2024Guideline
- A systematic review of the sex differences in risk factors for knee osteoarthritis.Rheumatology (Oxford, England) · 2023Pooled it
- Impact of Menopause and Clinical Considerations in Patients With Inflammatory Bowel Disease.Gastroenterology & hepatology · 2026Article
- Management of surgical menopause in female patients with bladder cancer undergoing radical cystectomy.Nature reviews. Urology · 2026Review
- Charting paths to sexual well-being: a comprehensive research agenda for fostering sexual health in Europe and beyond.International journal of impotence research · 2026Review
- [Russian eligibility criteria for prescription of menopausal hormone therapy to patients with cardiovascular and metabolic diseases. Agreement document of RKO, ROAG, RAE, EAT, AFR, RNMOT, RAGG].Problemy endokrinologii · 2026Article
- "Forever fertile": ovarian tissue cryopreservation for an extended reproductive lifespan.Journal of assisted reproduction and genetics · 2025Review
- Impact of sex and menopausal hormonal therapy on cardiovascular diseases in people with diabetes or prediabetes.Scientific reports · 2025Article
- Analysis of temporal and spatial changes in the global burden of hypertensive heart disease based on data from the Global Burden of Disease study database and future projections: 1990-2046.Frontiers in cardiovascular medicine · 2025Article
- EndoCompass Project: Research Roadmap for Reproductive and Developmental Endocrinology.Hormone research in paediatrics · 2025Review
- Hormone therapy and venous thromboembolism risk in women of menopausal age: a target trial emulation.European journal of epidemiology · 2024Article
- Epigenetic mechanisms regulate sex differences in cardiac reparative functions of bone marrow progenitor cells.NPJ Regenerative medicine · 2024Article
- Beyond hot flashes: Exploring the role of estrogen therapy in postmenopausal women for myocardial infarction prevention and recovery.Biomolecules & biomedicine · 2024Review
- Brazilian Guideline on Menopausal Cardiovascular Health - 2024.Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia · 2024Article
- Gender-specific genetic and epigenetic signatures in cardiovascular disease.Frontiers in cardiovascular medicine · 2024Review
- Statin Use and the Risk of Venous Thromboembolism in Women Taking Hormone Therapy.JAMA network open · 2023Article
- Article
- The Impact of Menopause on Cardiovascular Aging: A Comprehensive Review of Androgen Influences.Cureus · 2023Review
- Antiosteoporosis medications and cardiovascular disease: a population-based nationwide nested case-control study.Frontiers in pharmacology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A systematic review and meta-analysis of randomized controlled trials (RCTs) and observational studies was conducted to assess the association between menopausal hormone therapy and cardiovascular disease. The PubMed and EMBASE databases were searched for articles published from 2000 to 2019, using review methods based on a previous Cochrane review. Quality assessment of RCTs and observational studies was conducted using the Jadad scale and the Newcastle-Ottawa Scale, respectively. A total of 26 RCTs and 47 observational studies were identified. The study populations in the RCTs were older and had more underlying diseases than those in the observational studies. Increased risks of venous thromboembolism [summary estimate (SE), 95% confidence interval (CI): RCTs, 1.70, 1.33-2.16; observational studies, 1.32, 1.13-1.54] were consistently identified in both study types, whereas an increased risk of stroke in RCTs (SE: 1.14, 95% CI: 1.04-1.25) and a decreased risk of myocardial infarction in observational studies (SE: 0.79, 95% CI: 0.75-0.84) were observed. Differential clinical effects depending on timing of initiation, underlying disease, regimen type, and route of administration were identified through subgroup analyses. These findings suggest that underlying disease and timing of initiation should be carefully considered before starting therapy in postmenopausal women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.